IGF1R
3 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) (NCT05276063) | Sling Therapeutics, Inc. | 2022-07-01 |
Track IGF1R automatically
Every clearance here is in the API, with alerts when new ones post.